Browse CAT

Summary
SymbolCAT
Namecatalase
Aliases
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Peroxisome.
Domain PF00199 Catalase
PF06628 Catalase-related immune-responsive
Function

Occurs in almost all aerobically respiring organisms and serves to protect cells from the toxic effects of hydrogen peroxide. Promotes growth of cells including T-cells, B-cells, myeloid leukemia cells, melanoma cells, mastocytoma cells and normal and transformed fibroblast cells.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001101 response to acid chemical
GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001655 urogenital system development
GO:0001657 ureteric bud development
GO:0001666 response to hypoxia
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0006066 alcohol metabolic process
GO:0006091 generation of precursor metabolites and energy
GO:0006195 purine nucleotide catabolic process
GO:0006638 neutral lipid metabolic process
GO:0006639 acylglycerol metabolic process
GO:0006641 triglyceride metabolic process
GO:0006979 response to oxidative stress
GO:0007568 aging
GO:0007584 response to nutrient
GO:0008202 steroid metabolic process
GO:0008203 cholesterol metabolic process
GO:0009060 aerobic respiration
GO:0009166 nucleotide catabolic process
GO:0009314 response to radiation
GO:0009411 response to UV
GO:0009416 response to light stimulus
GO:0009636 response to toxic substance
GO:0009642 response to light intensity
GO:0009650 UV protection
GO:0009743 response to carbohydrate
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010193 response to ozone
GO:0010288 response to lead ion
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0014823 response to activity
GO:0014854 response to inactivity
GO:0015980 energy derivation by oxidation of organic compounds
GO:0016125 sterol metabolic process
GO:0019439 aromatic compound catabolic process
GO:0020027 hemoglobin metabolic process
GO:0031667 response to nutrient levels
GO:0032088 negative regulation of NF-kappaB transcription factor activity
GO:0032355 response to estradiol
GO:0032868 response to insulin
GO:0033189 response to vitamin A
GO:0033197 response to vitamin E
GO:0033273 response to vitamin
GO:0033591 response to L-ascorbic acid
GO:0034284 response to monosaccharide
GO:0034655 nucleobase-containing compound catabolic process
GO:0036293 response to decreased oxygen levels
GO:0036296 response to increased oxygen levels
GO:0042493 response to drug
GO:0042542 response to hydrogen peroxide
GO:0042743 hydrogen peroxide metabolic process
GO:0042744 hydrogen peroxide catabolic process
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0043434 response to peptide hormone
GO:0044270 cellular nitrogen compound catabolic process
GO:0045333 cellular respiration
GO:0045471 response to ethanol
GO:0046434 organophosphate catabolic process
GO:0046486 glycerolipid metabolic process
GO:0046686 response to cadmium ion
GO:0046700 heterocycle catabolic process
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0051262 protein tetramerization
GO:0051289 protein homotetramerization
GO:0051302 regulation of cell division
GO:0051781 positive regulation of cell division
GO:0055093 response to hyperoxia
GO:0070482 response to oxygen levels
GO:0070542 response to fatty acid
GO:0072001 renal system development
GO:0072073 kidney epithelium development
GO:0072163 mesonephric epithelium development
GO:0072164 mesonephric tubule development
GO:0072523 purine-containing compound catabolic process
GO:0072593 reactive oxygen species metabolic process
GO:0080184 response to phenylpropanoid
GO:0097305 response to alcohol
GO:0098754 detoxification
GO:0098869 cellular oxidant detoxification
GO:1901292 nucleoside phosphate catabolic process
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1901615 organic hydroxy compound metabolic process
GO:1901652 response to peptide
GO:1902652 secondary alcohol metabolic process
GO:1990748 cellular detoxification
Molecular Function GO:0004046 aminoacylase activity
GO:0004096 catalase activity
GO:0004601 peroxidase activity
GO:0016209 antioxidant activity
GO:0016684 oxidoreductase activity, acting on peroxide as acceptor
GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds
GO:0016811 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides
GO:0020037 heme binding
GO:0046906 tetrapyrrole binding
GO:0048037 cofactor binding
GO:0050661 NADP binding
GO:0050662 coenzyme binding
Cellular Component GO:0005758 mitochondrial intermembrane space
GO:0005777 peroxisome
GO:0005778 peroxisomal membrane
GO:0005782 peroxisomal matrix
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
GO:0031903 microbody membrane
GO:0031907 microbody lumen
GO:0031970 organelle envelope lumen
GO:0042579 microbody
GO:0044438 microbody part
GO:0044439 peroxisomal part
> KEGG and Reactome Pathway
 
KEGG hsa04068 FoxO signaling pathway
hsa04146 Peroxisome
hsa00380 Tryptophan metabolism
hsa00630 Glyoxylate and dicarboxylate metabolism
hsa01200 Carbon metabolism
Reactome R-HSA-2262752: Cellular responses to stress
R-HSA-3299685: Detoxification of Reactive Oxygen Species
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1430728: Metabolism
R-HSA-15869: Metabolism of nucleotides
R-HSA-6798695: Neutrophil degranulation
R-HSA-74259: Purine catabolism
R-HSA-73847: Purine metabolism
Summary
SymbolCAT
Namecatalase
Aliases
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CAT and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCAT
Namecatalase
Aliases
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CAT in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
Summary
SymbolCAT
Namecatalase
Aliases
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CAT in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4880.23
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.0080.667
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.110.949
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0120.981
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7710.676
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9490.686
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0230.959
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4340.817
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.460.829
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0420.983
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3650.905
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0030.973
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CAT in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.12.78.40.12
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.13.47.70.176
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117011.8-11.80.193
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311018.2-18.20.199
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCAT
Namecatalase
Aliases
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CAT. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCAT
Namecatalase
Aliases
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CAT. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CAT.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCAT
Namecatalase
Aliases
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CAT. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCAT
Namecatalase
Aliases
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CAT expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCAT
Namecatalase
Aliases
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CAT and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCAT
Namecatalase
Aliases
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CAT collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CAT.
ID Name Drug Type Targets #Targets
DB01213FomepizoleSmall MoleculeADH1A, ADH1B, ADH1C, CAT4